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Quantiﬁcation of neurodegeneration in animal models is typically assessed by time-
consuming and observer–dependent immunocytochemistry. This study aimed to in-
vestigate if newly developed ELISA techniques could provide an observer–independent,
cost–eﬀective and time saving tool for this purpose.
Neuroﬁlament-heavy chain (NfHSMI35 ), astrocytic glial ﬁbrillary acidic protein
(GFAP), S100B and ferritin, markers of axonal loss, gliosis, astrocyte activation and
microglial activation respectively, were quantiﬁed in the spinal cord homogenates of
mice with chronic relapsing experimental allergic encephalomyelitis (CREAE, n=8)
and controls (n=7). Levels of GFAP were found to be 3-fold elevated in CREAE (13
ng/mg protein) when compared to control animals (4.5 ng/mg protein, p<0.001).
The inverse was observed for NfHSMI35 (21 ng/mg protein vs. 63 ng/mg protein,
p<0.001), ferritin (542 ng/mg protein vs. 858 ng/mg protein, p<0.001) and S100B
(786 ng/mg protein vs 2080 ng/mg protein, N.S.). These ﬁndings were conﬁrmed
by immunocytochemistry, which demonstrated intense staining for GFAP and de-
creased staining for NfHSMI35 in CREAE compared to control animals.
These ﬁndings indicate that axonal loss and gliosis can be estimated biochemically
using the newly–developed ELISA assays for NfHSMI35 and GFAP. These assays may
facilitate the quantiﬁcation of pathological features involved in neurodegeneration.
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2Failure to halt the progression of multiple sclerosis (MS) with immunomodu-
latory agents and recent pathological insights has shown neurodegeneration to
be an important pathogenic component of MS [1–3] and provides impetus for
designing and assessing treatment paradigms in animal models. Axonal loss
correlates with permanent neurological disability in chronic relapsing experi-
mental allergic encephalomyelitis (CREAE) [1] and is typically assessed using
time–consuming and observer–dependent immunocytochemistry [1,2]. There-
fore simple quantitative surrogates for neurodegeneration would be useful.
In immunocytochemistry, GFAP has been used as a marker for astrogliosis and
S100B for activation of astrocytes, ferritin as a marker for microglial activation
and neuroﬁlaments (Nf) as a marker for axonal damage [3–6]. This study
examines the potential of ELISA–based methods to assess neurodegeneration
in CREAE.
1 Methods
Adult Biozzi ABH mice (6–8 weeks old) were housed in a light- and temper-
ature –controlled room and matched for age and sex in the experiment (50%
female in the CREAE and 43% female in the control group). CREAE was
induced as described previously [7]. In brief: Animals were injected s.c. in 2
sites of the ﬂank with a total of 0.3ml of Freund’s adjuvant:PBS (1:1) contain-
ing 1mg of syngeneic mouse spinal cord homogenate emulsiﬁed in Freund’s
incomplete adjuvant supplemented with 60g mycobacteria (Mycobacterium
tuberculosis H37Ra and M.butyricum (8:1)on day 0 and again on day 7. Ani-
mals were scored clinically on a scale ranging from 0 to 6, where 0 indicated
a normal animal, 1 a limp tail, 2 loss of the inverted righting reﬂex, 3 par-
3tial hind limb paralysis, 4 complete hindlimb paralysis, 5 moribund and 6
death [7]. After 60–80 days post–inoculation, the chronic phase of the disease
had been reached [8] and the animals were killed by CO2 intoxication. Im-
mediately after death the spinal column was cut in the cervical and lumbar
regions. A needle was inserted into the lumbar vertebral column and the spinal
cord ejected into an Eppendorf tube by a pressurised injection of saline. The
spinal cord which is the primary site of pathology in this model, [7] was snap–
frozen and stored at -70◦C until further analysis. Frozen tissue was used for
immunocytochemistry as described using polyclonal rabbit anti–cow GFAP
IgG (DAKO, Denmark) or polyclonal rabbit anti–bovine NfH IgG (Sigma,
UK) and FITC labelled swine anti–rabbit IgG (Dako) [7,8]. Photographs of
the ﬂuorescien images were digitally transformed into black–and–white slides
for better visualisation.
For protein analysis the spinal cord was suspended in sample buﬀer 1:5 v/w
containing a protease inhibitor cocktail (Sigma, No P 8340). Samples were
homogenised on ice by sonication and triturated 3 times through 19 and 21
gauge needles. Lipids were extracted by adding di–iso–propyl ether (1: 5,000)
prior to centrifugation at 20,000 g. The supernatant was stored at -70◦C.
S100B, GFAP and ferritin were measured as described [9,10,6]. Total protein
was measured using the standard Lowry method. The neuroﬁlament heavy
chain (NfHSMI35 ) was measured by ELISA: 96-well microtitre plates were
coated with 0.05 M carbonate buﬀer containing monoclonal anti NfHSMI35
(Sternberg Monoclonals Incorporate, 10 Burwood Court, Lutherville, MD
21093, SMI35) diluted 1:5000. The plates were washed with 0.67 M barbi-
tone buﬀer containing 5 mM EDTA, 0.1% BSA and 0.05% Tween. The plates
were blocked with 1% BSA and washed. Spinal cord homogenate was diluted
4in 0.67 M barbitone buﬀer containing 5 mM EDTA. After incubation and
wash a rabbit polyclonal anti–NfHSMI35 (Sigma) was diluted (1:1000) in the
sample buﬀer. After incubation and wash HRP-conjugated polyclonal swine
anti-rabbit IgG (DAKO, Denmark) was used as detecting antibody (1:1000).
The OPD (Sigma) colour reaction was stopped with 1 M hydrochloric acid and
the absorbances were read at 492 and 405 nm. All samples were processed in
duplicate. The antigen concentration was calculated from an internal standard
curve ranging from 0 ng/mL to 500 ng/mL (HPLC puriﬁed bovine NfHSMI35 ,
Aﬃniti Research Products, Exeter, UK) with an inter–assay covariation of
less then 15%. For clarity NfHSMI35 is referred to as NfH if measured by this
ELISA, based on the SMI35 capture monoclonal antibody.
All statistical analyses and graphs were performed using SAS software (V8.2
SAS Institute, Inc., Cary, North Carolina, USA). Individual values, the me-
dian, interquartile range (25–75% box) and 0–100% range (whiskers) were
shown in the ﬁgures because of the non–normal distribution. Statistical com-
parison was performed using Fisher’s exact test (=0.05). The cut–oﬀ for
categorical data analysis was set to 0% or 100% cumulative frequency of the
control group as appropriate. P–values of <0.05 were considered signiﬁcant.
2 Results
A 3–fold increase of median GFAP levels (13 ng/mg protein) in chronic EAE
animals was observed if compared to control animals (4.5 ng/mg protein, Fig.
1 A). In addition a more intense immunocytochemical staining was observed in
CREAE mice. The white matter of CREAE animals showed intense staining
for GFAP and widespread astrogliosis. Astrocytes of the CREAE grey matter
5were of larger conﬁguration with a greater number of extending processes
(Figure 2 A).
Levels of NfHSMI35 were approximately 3–fold lower in CREAE (21 ng/mg
protein) than in control mice (63 ng/mg protein, Fig. 1 B). The staining for
NfH was more intense in the white matter of control animals (Figure 2 B). It is
of note that the continuity of axonal projections could be followed. In CREAE
animals NfH staining was less intense, axonal continuity almost disappeared
and many axonal end–bulbs were observed (Figure 2 B).
Ferritin was less then 2–fold lower in CREAE (547 ng/mg protein) compared
to CTRL mice (858 ng/mg protein, Fig. 1 C), median S100B levels were about
2.6–fold lower in CREAE (786 ng/mg protein) than in CTRL mice (2080
ng/mg protein, Fig. 1 D).
Seven out of 8 (88%) CREAE animals had GFAP levels above the cut–oﬀ and
by deﬁnition none (0%) of the control animals had GFAP levels above the
cut–oﬀ (p<0.001). For NfHSMI35 0/8 (0%) of the CREAE and 7/7 (100%) of
the control animals had levels above the cut–oﬀ (p<0.001). For ferritin 1/7
(13%) of the CREAE and 7/7 (100%) of the control mice had levels above
cutoﬀ (p<0.001). For S100B 3/8 (38%) of the CREAE and 0/7 (100%) of the
control mice had levels above the cut–oﬀ, but this did not reach statistical
signiﬁcance. For the small number of animals investigated we found no statis-
tically signiﬁcant diﬀerence in proportions of animals with moderately (score
 4) vesus severe (score of 5) disability.
63 Discussion
The observation that GFAP levels were 3–fold higher in the spinal cords of
mice with chronic EAE compared to control animals is in keeping with the
observation that extensive gliosis is a pathological hallmark of the late stages of
the disease [4,7]. However gliosis is diﬃcult to quantify by immuncytochemical
techniques and usually done by counting cells, and the number and length
of extending processes. The ﬁnding of grey matter astrogliosis and elevated
GFAP levels is in line with previous results from human multiple sclerosis
post–mortem tissue [6].
NfHSMI35 levels were signiﬁcantly lower in chronic EAE animals when com-
pared to control animals. This biochemical result conﬁrms the immunocyto-
chemical observation of loss of axons in these animals [7,1]. In the light of
recent data on axonal loss in MS [2,3] and severe axonal loss in the spinal
cord of EAE [1], it is of particular interest that not only the overall staining
intensity for NfH decreased, but also that axonal continuity almost completely
disappeared. Counting axons might be particularly diﬃcult in these situations
and would only represent an estimate at the site of section. The measurement
of the total NfHSMI35 content is likely to be a more robust overall estimate of
the bulk of remaining axons.
Ferritin and S100B are distinct from GFAP and NfHSMI35 since they do not
provide the scaﬀolding of the cytoskeleton, but are a product of the cellular
metabolism for speciﬁc functional purposes. The decrease of ferritin suggests
that the gliotic tissue transformation is paralleled by speciﬁc alteration of the
glial metabolism. Whether or not this involves loss of neurotrophic support
7will need to be studied in experiments focusing on neurodegeneration.
In summary these ﬁndings demonstrate that axonal loss and gliosis can be
quantiﬁed biochemically by measuring NfHSMI35 and GFAP levels in the spinal
cord tissue homogenate of animals with CREAE. These ﬁndings support the
notion that brain–speciﬁc proteins emerge as surrogate markers and secondary
outcome measures for neurodegenerative processes. The methods presented
should be cross–validated with other markers and may provide time- and cost–
eﬀective tools for experimental models investigating neurodegeneration.
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9Table 1: Control (CTRL) and CREAE ABH mice spinal
cord homogenate. Levels of brain{specic proteins are
shown in g/mg protein. Median (range).
Protein ng/mg protein CTRL mice CREAE mice p–value
GFAP 4.5 (1.4–5.2) 13 (5.0–26.4) p<0.001
S100B 2080 (852–3107) 786 (219–1466) N.S.
NfHSMI35 63 (53–84) 21 (9–44) p<0.001




















































































































Fig. 1. Mice spinal cord tissue homogenates. Scatter and box-whisker plot for (A)
GFAP (ng/mg protein), (B) NfHSMI35 (ng/mg protein), (C) Ferritin (ng/mg pro-
tein) and (D) S100B (ng/mg protein) levels in control (CTRL) and chronic EAE
(CREAE) mice. Severely disabled animals are indicated by closed circles.
11Fig. 2. Immunocytochemistry on longitudinal fresh frozen spinal cord sections of 3
control and 3 CREAE animals (x40). (A) GFAP staining for white and grey matter.
More intense staining is observed in the CREAE spinal cord: in particular, the grey
matter astrocytes are larger with more and longer processes. (B) NfH staining in
white matter. Axonal tracts can be followed in control but not in CREAE animals.
The staining in CREAE animals is less intense and many axonal end-bulbs are seen.
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